Tagomics, a Cambridge, UK-based developer of a platform for comprehensive disease insight and diagnosis, raised £6.7M in funding.
The round was led by Calculus Capital, with participation from Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures and the MEIF Proof of Concept & Early Stage Fund, Meltwind and OMX Ventures.
This funding followed a £1.6M pre-seed round led by IQ Capital and Start Codon and including grant funding from Innovate UK.
The company intends to use the funds to accelerate its scientific research and product development, with the goal of delivering improvements in cancer and other diseases’ diagnosis and treatment.
Launched in July 2020 as a spin-out from the University of Birmingham, and led by CEO Dr. Jack Kennefick, Tagomics has developed a platform that combines “omics” technologies, including genomics (detecting mutations), epigenomics (studying chemical ‘switches’ on the genome), and fragmentomics (the analysis of DNA fragmentation patterns in the blood). By integrating these methods and applying advanced data analysis and machine learning, the platform can help discover new markers of cancer and develop strategic partnerships, advancing drug development and therapy selection for patients.
Commenting on the news, Jack Kennefick said: “The multiomic capabilities of Tagomics’ approach enable more comprehensive insight into diseases such as cancer; these insights will enable us to develop simpler and more accurate means of diagnosing and treating patients. We’re pleased to welcome such an experienced group of investors on board to help us accelerate the development of our platform and support our efforts in expanding the capabilities of genomic medicine.”
FinSMEs
21/02/2024